Press release from Companies
Publicerat: 2021-11-09 10:00:00
(Oslo, 9 November 2021) Genetic Analysis AS ("GA" or "the Company") hereby publishes the interim report for the period January 1 – September 30, 2021. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
Genetic Analysis CEO Ronny Hermansen comments: Q3 2021 (01.07.2021 – 30.09.2021) Q1 – Q3 2021 (01.01.2021 – 30.09.2021) Highlights Q3 2021 Highlights after the period For further information, please contact: Eilert Aamodt, Chief Financial Officer About Genetic Analysis:
“We see the microbiome as a gamechanger in health and medicine moving forward. The Company’s recent financial injection paired up with our pioneering technology puts GA in an excellent position to realize our goal of being at the forefront of microbiome diagnostics and generate long-term value to its shareholders.”
Ronny Hermansen, Chief Executive Officer
E-mail: rh@genetic-analysis.com
E-mail: ea@genetic-analysis.com
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs 22 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering. www.genetic-analysis.com